Clinical Trial Update: High Dose Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil in Preventing Graft Versus Host Disease in Patients With Hematological Malignancies Undergoing Myeloablative or Reduced Intensity Donor Stem Cell Transplant [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating high-dose cyclophosphamide, tacrolimus, and mycophenolate mofetil to prevent graft-versus-host disease in hematologic malignan…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia with Myelodysplasia-related Changes
• Chronic Lymphocytic Leukemia
• Diffuse Large B-cell Lymphoma
• Follicular Lymphoma
• Graft-versus-host Disease
• Hodgkin Lymphoma
• Leukemia
• Mantle Cell Lymphoma
• Marginal Zone Lymphoma
• Myelodysplastic Syndrome
• Myelogenous Leukemia Bcr-abl1 Positive
• Myeloproliferative Neoplasm
• Plasma Cell Myeloma
• Small Lymphocytic Lymphoma

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• MYCOPHENOLATE MOFETIL (MYCOPHENOLATE MOFETIL)
• Tacrolimus (Tacrolimus)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Acute Leukemia, Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2023-06-09